Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacqulyne P Robichaux

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Cancer Cell|August 13, 2021
ARTEMIS highlights VEGF inhibitors as effective partners for EGFR TKIs in EGFR mutant NSCLCXiuning Le, Monique B Nilsson, Jacqulyne P Robichaux, et al.
Anticancer Research|March 6, 2014
Morphometric and fractal dimension analysis identifies early neoplastic changes in mammary epithelium of MMTV-cNeu miceJohn W Fuseler, Jacqulyne P Robichaux, Huda I Atiyah, et al.
Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences|November 9, 2016
Left-right analysis of mammary gland development in retinoid X receptor-α+/- miceJacqulyne P Robichaux, John W Fuseler, Shrusti S Patel, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 23, 2026
Adaptive feedback signaling via the FAK/SRC pathway promotes KRAS G12C inhibitor resistanceHibiki Udagawa, Yuji Shibata, Monique B Nilsson, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 7, 2023
HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting StrategiesHibiki Udagawa, Monique B Nilsson, Jacqulyne P Robichaux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 22, 2021
Poziotinib for Patients With <i>HER2</i> Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II TrialYasir Y Elamin, Jacqulyne P Robichaux, Brett W Carter, et al.
Clinical Lung Cancer|October 22, 2018
Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non-small-cell Lung Cancer (NSCLC)Yasir Y Elamin, Daniel R Gomez, Mara B Antonoff, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 26, 2026
Compound EGFR mutations are predominantly PACC (P-loop and alpha-C helix compressing) mutations with increased responsiveness to second- vs third-generation tyrosine kinase inhibitorsXimeng Liu, Moses Stamboulian, Maxime Borgeaud, et al.
Nature Medicine|April 25, 2018
Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancerJacqulyne P Robichaux, Yasir Y Elamin, Zhi Tan, et al.
Nature Communications|September 24, 2025
Poziotinib for EGFR exon 20-insertion NSCLC: Clinical efficacy of the phase 2 ZENITH trial and differential impact of EGFR exon 20 insertion location on sensitivityXiuning Le, Jacqulyne P Robichaux, Monique Nilsson, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Cancer Cell|August 13, 2021
ARTEMIS highlights VEGF inhibitors as effective partners for EGFR TKIs in EGFR mutant NSCLCXiuning Le, Monique B Nilsson, Jacqulyne P Robichaux, et al.
Anticancer Research|March 6, 2014
Morphometric and fractal dimension analysis identifies early neoplastic changes in mammary epithelium of MMTV-cNeu miceJohn W Fuseler, Jacqulyne P Robichaux, Huda I Atiyah, et al.
Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences|November 9, 2016
Left-right analysis of mammary gland development in retinoid X receptor-α+/- miceJacqulyne P Robichaux, John W Fuseler, Shrusti S Patel, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 23, 2026
Adaptive feedback signaling via the FAK/SRC pathway promotes KRAS G12C inhibitor resistanceHibiki Udagawa, Yuji Shibata, Monique B Nilsson, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 7, 2023
HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting StrategiesHibiki Udagawa, Monique B Nilsson, Jacqulyne P Robichaux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 22, 2021
Poziotinib for Patients With <i>HER2</i> Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II TrialYasir Y Elamin, Jacqulyne P Robichaux, Brett W Carter, et al.
Clinical Lung Cancer|October 22, 2018
Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non-small-cell Lung Cancer (NSCLC)Yasir Y Elamin, Daniel R Gomez, Mara B Antonoff, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 26, 2026
Compound EGFR mutations are predominantly PACC (P-loop and alpha-C helix compressing) mutations with increased responsiveness to second- vs third-generation tyrosine kinase inhibitorsXimeng Liu, Moses Stamboulian, Maxime Borgeaud, et al.
Nature Medicine|April 25, 2018
Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancerJacqulyne P Robichaux, Yasir Y Elamin, Zhi Tan, et al.
Nature Communications|September 24, 2025
Poziotinib for EGFR exon 20-insertion NSCLC: Clinical efficacy of the phase 2 ZENITH trial and differential impact of EGFR exon 20 insertion location on sensitivityXiuning Le, Jacqulyne P Robichaux, Monique Nilsson, et al.
Pageof 2